Atractylenolide III, also known as ICodonolactone, constitutes the primary active compound of the Atractylodes rhizome and exhibits the capability to induce apoptosis in lung cancer cells. It is recognized for its oral efficacy as a gastroprotective agent .
体内研究
Atractylenolide III, administered orally at doses of 5 and 10 mg/kg, demonstrates gastroprotective effects and reduces gastric ulcers induced by 70% ethanol in rats by up to 70%[2].
Atractylenolide III, when administered at 30 mg/kg through oral gavage for either 14 or 28 days, alleviates depressive- and anxiogenic-like behaviors in rat models of depression. This effect is observed in models induced by lipopolysaccharide (LPS) and chronic unpredictable mild stress (CUMS)[5].
体外研究
Atractylenolide III, at concentrations ranging from 1 to 100 μM over 48 hours, induces apoptosis in A549 cells, as evidenced by the activation of caspase-3 and caspase-9 and the cleavage of PARP[1].
Atractylenolide III, in concentrations between 1 and 100 μM over a period of 72 hours, inhibits proliferation and angiogenesis, as indicated by tube formation, in Human Umbilical Vein Endothelial Cells (HUVECs)[1].
Atractylenolide III, at concentrations of 1-100 μM, inhibits the production of proinflammatory cytokines (IL-6, IL-1β, TNF-α, and IL-8) induced by thymic stromal lymphopoietin (TSLP) in HMC-1 cells[4].
Atractylenolide III/白术内酯 III 细胞实验
Cell Line
Concentration
Treated Time
Description
References
HepG2 cells
12.5, 25, 50 µg/ml
24 h
To evaluate the effects of ATL III on lipid metabolism, ATL III treatment significantly reduced FFAs-induced lipid accumulation in HepG2 cells.
Int J Biol Sci. 2022 Jan 31;18(4):1594-1611
bEnd.3 cells
10 µM
2 h
To evaluate the effect of Atractylenolide III combined with Atractylenolide I and Paeoniflorin on the tube formation of bEnd.3 cells. The results showed that the combination significantly promoted cell tube formation.
Chin Med. 2024 Jan 4;19(1):3
bEnd.3 cells
10 µM
16 h
To evaluate the effect of Atractylenolide III combined with Paeoniflorin on the migration of bEnd.3 cells. The results showed that the combination significantly promoted cell migration.
Chin Med. 2024 Jan 4;19(1):3
bEnd.3 cells
10 µM
24 h
To evaluate the effect of Atractylenolide III combined with Atractylenolide I and Paeoniflorin on the proliferation of bEnd.3 cells. The results showed that the combination significantly promoted cell proliferation.
Chin Med. 2024 Jan 4;19(1):3
Rat HSC cell line T6
20, 30 or 40 mM
Atractylenolide III inhibits ASCT2 expression, induces HSC senescence, and reduces proinflammatory SASP production
Acta Pharm Sin B. 2022 Sep;12(9):3618-3638
Atractylenolide III/白术内酯 III 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6J mice
HFD-induced NAFLD model
Tail intravenous injection
10 mg/kg
Every other day for 4 weeks
ATL III treatment significantly ameliorated liver injury and hepatic lipid accumulation in the HFD-induced NAFLD mouse model, reducing serum levels of ALT, AST, TG, TC, and LDL.
Int J Biol Sci. 2022 Jan 31;18(4):1594-1611
ICR mice
CCl4-induced liver fibrosis model
Intraperitoneal injection
20, 30 or 40 mg/kg
Three times a week for 8 weeks
Atractylenolide III induces HSC senescence by inhibiting ASCT2 and ameliorates liver fibrosis
搜索
